Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 15, 2015, Pages 4737-4742

  Andruska, Neal D ^a,b   Zheng, Xiaobin ^a   Yang, Xujuan ^b   Mao, Chengjian ^a   Cherian, Mathew M ^a,b   Mahapatra, Lily ^a,b   Helferich, William G ^b,c   Shapiro, David J ^a,b,c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Breast cancer; Drug discovery; Estrogen receptor; Ovarian cancer; Unfolded protein response

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIESTROGEN; BHPI; CALCIUM CHANNEL; CALCIUM ION; ELONGATION FACTOR 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA INHIBITOR; ESTROGEN RECEPTOR ANTAGONIST; FULVESTRANT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 2ALPHA; INOSITOL 1,4,5 TRISPHOSPHATE; PHOSPHOLIPASE C GAMMA; PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; 3,3-BIS(4-HYDROXYPHENYL)-7-METHYL-1,3-DIHYDRO-2H-INDOL-2-ONE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA, HUMAN; INDOLE DERIVATIVE; MOLECULAR LIBRARY;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL MEMBRANE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ESTROGEN ACTIVITY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; TUMOR REGRESSION; TUMOR XENOGRAFT; UNFOLDED PROTEIN RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL LINE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HEPG2 CELL LINE; METABOLISM; MOLECULAR LIBRARY; NUDE MOUSE; PHARMACOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

EUKARYOTA;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HELA CELLS; HEP G2 CELLS; HUMANS; INDOLES; MCF-7 CELLS; MICE, NUDE; MOLECULAR STRUCTURE; PROTEIN BIOSYNTHESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMALL MOLECULE LIBRARIES; TUMOR BURDEN; UNFOLDED PROTEIN RESPONSE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928019082     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1403685112     Document Type: Article

References (36)

1. Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116(3):561-570.
2. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631-643.
3. Tyson JJ, et al. (2011) Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat Rev Cancer 11(7):523-532.
4. Yu KD, Wu J, Shen ZZ, Shao ZM (2012) Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: Implication for extended endocrine therapy. J Clin Endocrinol Metab 97(12):E2201-E2209.
5. Emons G, et al.; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) (2013) Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologische Onkologie. Gynecol Oncol 129(3):495-499.
6. Simpkins F, et al. (2012) Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res 18(21): 5911-5923.
7. Smyth JF, et al. (2007) Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13(12): 3617-3622.
8. Jemal A, et al. (2004) Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101(1):3-27.
9. Benod C, et al. (2013) Structure-based discovery of antagonists of nuclear receptor LRH-1. J Biol Chem 288(27):19830-19844.
10. Kretzer NM, et al. (2010) A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor alpha. J Biol Chem 285(53):41863-41873.
11. Thiruchelvam PT, et al. (2011) The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Res Treat 127(2):385-396.
12. Wang LH, et al. (2006) Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 10(6):487-499.
13. Andruska N, Mao C, Cherian M, Zhang C, Shapiro DJ (2012) Evaluation of a luciferase-based reporter assay as a screen for inhibitors of estrogen-ERα-induced proliferation of breast cancer cells. J Biomol Screen 17(7):921-932.
14. Andruska N, Zheng X, Yang X, Helferich WG, Shapiro DJ (2014) Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer. Oncogene, 10.1038/onc.2014.292.
15. Rimawi MF, et al. (2011) Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 17(6):1351-1361.
16. Ohta T, et al. (2006) Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 147(4):1761-1769.
17. Ali AY, Abedini MR, Tsang BK (2012) The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene 31(17):2175-2186.
18. Vergara D, et al. (2012) Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomedicine (Lond Print) 8(6):891-899.
19. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG (2002) Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 62(9):2474-2477.
20. Wong H, et al. (2012) Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 18(14): 3846-3855.
21. Abukhdeir AM, et al. (2008) Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci USA 105(1):288-293.
22. Fowler AM, Solodin NM, Valley CC, Alarid ET (2006) Altered target gene regulation controlled by estrogen receptor-alpha concentration. Mol Endocrinol 20(2):291-301.
23. Ikeda Y, et al. (2012) Estrogen regulates hepcidin expression via GPR30-BMP6-dependent signaling in hepatocytes. PLoS ONE 7(7):e40465.
24. Ron D, Walter P (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8(7):519-529.
25. Walter P, Ron D (2011) The unfolded protein response: From stress pathway to homeostatic regulation. Science 334(6059):1081-1086.
26. DeSouza N, et al. (2002) Protein kinase A and two phosphatases are components of the inositol 1,4,5-trisphosphate receptor macromolecular signaling complex. J Biol Chem 277(42):39397-39400.
27. Li T, et al. (2009) SH2D4A regulates cell proliferation via the ERalpha/PLC-gamma/PKC pathway. BMB Rep 42(8):516-522.
28. Harrington WR, et al. (2006) Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol 20(3):491-502.
29. Leprivier G, et al. (2013) The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 153(5):1064-1079.
30. Proud CG (2007) Signalling to translation: How signal transduction pathways control the protein synthetic machinery. Biochem J 403(2):217-234.
31. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121(2):179-193.
32. Luo B, Lee AS (2013) The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 32(7):805-818.
33. Rutkowski DT, et al. (2006) Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol 4(11):e374.
34. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A (2009) Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 625(1-3):234-246.
35. Thorpe SM, Christensen IJ, Rasmussen BB, Rose C (1993) Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer 29A(7):971-977.
36. Kandoth C, et al.; Cancer Genome Atlas Research Network (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67-73.